# Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery

> **NCT02855086** · PHASE1,PHASE2 · TERMINATED · sponsor: **Eben Rosenthal** · enrollment: 3 (actual)

## Conditions studied

- Brain Neoplasm
- Malignant Glioma

## Interventions

- **BIOLOGICAL:** Cetuximab
- **DRUG:** Cetuximab-IRDye 800CW
- **PROCEDURE:** Tumor resection

## Key facts

- **NCT ID:** NCT02855086
- **Lead sponsor:** Eben Rosenthal
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2016-11-08
- **Final completion:** 2016-11-22
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** logistics
- **Last updated:** 2020-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02855086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02855086, "Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02855086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*